Form 4: Gilead Sciences SVP, Controllership, Sandra Patterson, Reports Stock Transactions

Gilead Sciences' SVP, Controllership, Sandra Patterson, reports the acquisition of common stock and restricted stock units.

Summary

• Sandra Patterson, SVP, Controllership at Gilead Sciences, Inc., reported several transactions on December 10, 2024.
• These transactions include the acquisition of 901 shares of common stock.
• Additionally, 408 restricted stock units were acquired at a price of $92.34 per unit.
• The restricted stock units vest over four years, with 25% vesting on the first anniversary of the grant date and the remaining 75% vesting quarterly at 6.25% thereafter.

Sentiment

Score: 6

Explanation: The document is a routine filing of stock transactions by an executive, which is neither particularly positive nor negative. It indicates standard compensation practices.

Positives

• The acquisition of stock and restricted stock units by a senior executive could be seen as a positive sign of confidence in the company's future.

Industry Context

Executive stock transactions are a common practice in publicly traded companies and are often seen as a reflection of management's confidence in the company's performance and future prospects.

Comparison to Industry Standards

• Stock-based compensation, including restricted stock units, is a standard practice for executive compensation in the pharmaceutical industry.
• Vesting schedules, such as the four-year schedule described, are also common to incentivize long-term performance and retention.

Stakeholder Impact

• The stock transactions may have a minor positive impact on shareholder sentiment, as it indicates executive confidence.

Key Dates

Keywords

Gilead Sciences, Stock Transactions, Restricted Stock Units, Sandra Patterson, Executive Compensation, Vesting Schedule